Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4050202 | PMC |
| http://dx.doi.org/10.1200/JCO.2013.51.7946 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Proteins and pathways involved in inflammation are longitudinally associated with total body bone mineral density among primarily hispanic overweight/obese adolescents and young adults.
J Bone Miner Res
January 2025
Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States.
Bone mineral density (BMD), an important marker of bone health, is regulated by a complex interaction of proteins. Plasma proteomic analyses can contribute to identification of proteins associated with changes in BMD. This may be especially informative in stages of bone accrual and peak BMD achievement (i.
View Article and Find Full Text PDFCYP2D6 activity in patients with metastatic breast cancer treated with single agent tamoxifen: results from ECOG-ACRIN E3108.
Breast Cancer Res Treat
October 2024
Indiana University School of Medicine, Indianapolis, IN, USA.
Article Synopsis
- - The study examined how genetic variations in the CYP2D6 gene and resulting endoxifen levels affect breast cancer outcomes in patients taking tamoxifen.
- - Conducted with 113 patients with advanced hormone receptor-positive breast cancer, it compared those with poor CYP2D6 metabolism to those with normal or intermediate metabolism regarding progression-free survival (PFS).
- - Results showed no significant relationship between CYP2D6 status, endoxifen concentrations, and PFS, possibly due to the small sample size and issues with sample collection in the trial.
Improving clinical trial enrollment in minority racial and ethnic patients with gynecologic malignancy.
Gynecol Oncol Rep
October 2024
Department of Obstetrics and Gynecology and Medicine, Division of Gynecologic Oncology, Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA.
Purpose: Racial and ethnic minorities remain underrepresented in clinical trials . Underrepresentation of racial groups leads to the selection of therapeutic interventions that may not be representative of the population expected to use the medicine. This study evaluates the effectiveness of a set of implementation strategies to increase underrepresented patients in gynecologic cancer clinical trials.
View Article and Find Full Text PDFImproving diverse patient enrollment in clinical trials, focusing on Hispanic and Asian populations: recommendations from an interdisciplinary expert panel.
Int J Gynecol Cancer
January 2025
Mount Sinai Medical Center and Florida International University, Miami Beach, Florida, USA.
Lack of patient diversity in clinical trial enrollment remains an obstacle to achieving equitable healthcare outcomes. Under-representation has resulted in non-generalizable clinical knowledge, inequitable access to treatment, and health disparities among minority and disadvantaged groups. A multidisciplinary panel was convened to consider the challenges of diverse patient accrual and provide actionable solutions to improve representation in clinical trials.
View Article and Find Full Text PDFAssociation Between State Medicaid Policies and Accrual of Black or Hispanic Patients to Cancer Clinical Trials.
J Clin Oncol
September 2024
Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
Purpose: It is unknown whether Medicaid expansion under the Affordable Care Act (ACA) or state-level policies mandating Medicaid coverage of the routine costs of clinical trial participation have ameliorated longstanding racial and ethnic disparities in cancer clinical trial enrollment.
Methods: We conducted a retrospective, cross-sectional difference-in-differences analysis examining the effect of Medicaid expansion on rates of enrollment for Black or Hispanic nonelderly adults in nonobservational, US cancer clinical trials using data from Medidata's Rave platform for 2012-2019. We examined heterogeneity in this effect on the basis of whether states had pre-existing mandates requiring Medicaid coverage of the routine costs of clinical trial participation.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!